![Patrick Crutcher](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrick Crutcher
Keine laufenden Positionen mehr
Vermögen: 11 Mio $ am 30.06.2026
Profil
Patrick J.
Crutcher is Chief Executive Officer at Mach5 Therapeutics, Inc. and Independent Director at Amanat Acquisition Corp.
Former roles include President & Chief Executive Officer at AlmataBio, Inc., Chairman & President at Ichorion Therapeutics, Inc. from 2017 to 2018, and Chief Strategy Officer at Avalo Therapeutics, Inc. in 2019.
Education includes graduate studies at the University of California, Los Angeles and undergraduate studies at the University of Illinois.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
AVALO THERAPEUTICS INC 1,04 % | 06.08.2025 | 549.467 ( 1,04 % ) | 10 Mio $ | 30.06.2026 |
iBio, Inc.
 iBio, Inc. Pharmaceuticals: OtherHealth Technology Engages in the development and commercialization of vaccines and therapeutic proteins 0,87 % | 30.06.2025 | 300.438 ( 0,87 % ) | 525 767 $ | 30.06.2026 |
1,15 % | 20.05.2026 | 25.000 ( 1,15 % ) | 254 000 $ | 30.06.2026 |
Jasper Therapeutics, Inc.
 Jasper Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company which engages in enabling cures through hematopoietic stem cell therapy 1,85 % | 16.07.2026 | 518.331 ( 1,85 % ) | 218 217 $ | 30.06.2026 |
Jasper Therapeutics, Inc.
Jasper Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company which engages in enabling cures through hematopoietic stem cell therapy 9,98 % | 20.07.2026 | 463.452 ( 9,98 % ) | 195 113 $ | 30.06.2026 |
Aktive Positionen von Patrick Crutcher
| Unternehmen | Position | Beginn |
|---|
Ehemalige bekannte Positionen von Patrick Crutcher
| Unternehmen | Position | Ende |
|---|---|---|
| AVALO THERAPEUTICS, INC. | Corporate Officer/Principal | 01.11.2019 |
Ichorion Therapeutics, Inc.
 Ichorion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceutical products | Vorstandsvorsitzender | 01.09.2018 |
Ausbildung von Patrick Crutcher
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
3
Beziehungen ersten Grades
4
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 4 |
|---|---|
University of California, Los Angeles
 University of California, Los Angeles Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Illinois
 University of Illinois Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Avalo Therapeutics, Inc.
 Avalo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes therapeutics for patients with unmet clinical need in immunology and rare genetic diseases | Health Technology |
Ichorion Therapeutics, Inc.
Ichorion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceutical products | Health Technology |
